Development and comparison of bioanalytical methods to measure free analyte

Free analyte is measured to be able to understand the pharmacological effects of a drug in the body, the binding to its ligand, and the effective drug level among other things. Thereby, it is important with correct measurements of free analyte, although it is not that easy to achieve since overestim...

Full description

Bibliographic Details
Main Author: Pihlblad, Alma
Format: Others
Language:English
Published: Uppsala universitet, Institutionen för biologisk grundutbildning 2020
Subjects:
Online Access:http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-413669
id ndltd-UPSALLA1-oai-DiVA.org-uu-413669
record_format oai_dc
spelling ndltd-UPSALLA1-oai-DiVA.org-uu-4136692020-06-19T03:33:46ZDevelopment and comparison of bioanalytical methods to measure free analyteengPihlblad, AlmaUppsala universitet, Institutionen för biologisk grundutbildning2020BiotechnologyimmunoassayGyrolabELISAimmunologyfree analyteoverestimationaffinityAvastinbevacizumabLucentisranibizumabVEGFpharmacokineticpharmacodynamicIndustrial BiotechnologyIndustriell bioteknikFree analyte is measured to be able to understand the pharmacological effects of a drug in the body, the binding to its ligand, and the effective drug level among other things. Thereby, it is important with correct measurements of free analyte, although it is not that easy to achieve since overestimations can occur. In this project, several immunoassays were developed for the bioanalytical methods Gyrolab and ELISA to measure free analyte, where the biotherapeutics Avastin® and Lucentis®, and the ligand VEGF were used as analytes. One difference between the methods is the short contact time of just a few seconds for Gyrolab compared to the sample incubation time of a couple of hours for ELISA. One difference between the antibodies is that Lucentis is an affinity-matured Fab region, and therefore, has a stronger affinity to VEGF compared to Avastin. When free Avastin was measured, the difference was significant, with ELISA estimating higher concentrations compared to Gyrolab. However, this was not the case for all assays. In some cases, this was probably due to differences between the methods that could not be seen. Otherwise, the results with no difference between the methods, when measuring free analyte with Lucentis as the drug, were expected due to the stronger affinity and longer halftime of dissociation. However, the difference with the longer sample incubation time for ELISA compared to the short contact time for Gyrolab seems to influence the measurement of free analyte, depending on the affinity of the components being measured. Student thesisinfo:eu-repo/semantics/bachelorThesistexthttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-413669UPTEC X ; 20009application/pdfinfo:eu-repo/semantics/openAccess
collection NDLTD
language English
format Others
sources NDLTD
topic Biotechnology
immunoassay
Gyrolab
ELISA
immunology
free analyte
overestimation
affinity
Avastin
bevacizumab
Lucentis
ranibizumab
VEGF
pharmacokinetic
pharmacodynamic
Industrial Biotechnology
Industriell bioteknik
spellingShingle Biotechnology
immunoassay
Gyrolab
ELISA
immunology
free analyte
overestimation
affinity
Avastin
bevacizumab
Lucentis
ranibizumab
VEGF
pharmacokinetic
pharmacodynamic
Industrial Biotechnology
Industriell bioteknik
Pihlblad, Alma
Development and comparison of bioanalytical methods to measure free analyte
description Free analyte is measured to be able to understand the pharmacological effects of a drug in the body, the binding to its ligand, and the effective drug level among other things. Thereby, it is important with correct measurements of free analyte, although it is not that easy to achieve since overestimations can occur. In this project, several immunoassays were developed for the bioanalytical methods Gyrolab and ELISA to measure free analyte, where the biotherapeutics Avastin® and Lucentis®, and the ligand VEGF were used as analytes. One difference between the methods is the short contact time of just a few seconds for Gyrolab compared to the sample incubation time of a couple of hours for ELISA. One difference between the antibodies is that Lucentis is an affinity-matured Fab region, and therefore, has a stronger affinity to VEGF compared to Avastin. When free Avastin was measured, the difference was significant, with ELISA estimating higher concentrations compared to Gyrolab. However, this was not the case for all assays. In some cases, this was probably due to differences between the methods that could not be seen. Otherwise, the results with no difference between the methods, when measuring free analyte with Lucentis as the drug, were expected due to the stronger affinity and longer halftime of dissociation. However, the difference with the longer sample incubation time for ELISA compared to the short contact time for Gyrolab seems to influence the measurement of free analyte, depending on the affinity of the components being measured.
author Pihlblad, Alma
author_facet Pihlblad, Alma
author_sort Pihlblad, Alma
title Development and comparison of bioanalytical methods to measure free analyte
title_short Development and comparison of bioanalytical methods to measure free analyte
title_full Development and comparison of bioanalytical methods to measure free analyte
title_fullStr Development and comparison of bioanalytical methods to measure free analyte
title_full_unstemmed Development and comparison of bioanalytical methods to measure free analyte
title_sort development and comparison of bioanalytical methods to measure free analyte
publisher Uppsala universitet, Institutionen för biologisk grundutbildning
publishDate 2020
url http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-413669
work_keys_str_mv AT pihlbladalma developmentandcomparisonofbioanalyticalmethodstomeasurefreeanalyte
_version_ 1719322320075489280